small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with relapsed small cell lung cancer who have been treated with chemotherapy, radiation therapy alone or in combination, and who will receive anticancer therapy
Exclusion criteria
Exclusion criteria: Patients with any of the following 1. have a serious comorbidity 2. have only one measurable or evaluable lesion at the time of enrollment that is amenable to resection or radiation therapy 3. Previous invasive surgical treatment as judged by the investigator within 28 days prior to the first dose of the clinical trial. 4. Patients with a clinically more active malignancy than small cell lung cancer (except those with negligible risk of death or metastasis and a 5-year survival rate of at least 90%) 5. pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival in chemotherapy for relapsed small cell lung cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival at 6 months, overall survival, duration of response, and safety in chemoterapy for relapsed small cell lung cancer | — |
Countries
Japan
Contacts
Public ContactYoshihiro Kitahara
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed